A Two-Part Study to Evaluate the Effect of CYP3A4 Inhibition (Itraconazole-Part 1) and CYP1A2 Inhibition (Ciprofloxacin - Part 2) on the Single-Dose Pharmacokinetics of Pracinostat in Healthy Nonsmoking Subjects

Trial Profile

A Two-Part Study to Evaluate the Effect of CYP3A4 Inhibition (Itraconazole-Part 1) and CYP1A2 Inhibition (Ciprofloxacin - Part 2) on the Single-Dose Pharmacokinetics of Pracinostat in Healthy Nonsmoking Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Pracinostat (Primary) ; Ciprofloxacin; Itraconazole
  • Indications Acute myeloid leukaemia; Haematological malignancies; Leukaemia; Myelodysplastic syndromes; Myelofibrosis; Prostate cancer; Sarcoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors MEI Pharma
  • Most Recent Events

    • 17 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov
    • 22 Sep 2014 Planned End Date changed from 1 Jul 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
    • 22 Sep 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top